glp-1 agonist Classification of currently available glucagon-like peptide-1 receptor Understanding GLP-1 Agonists
Description
The FDA also recommends examining hard clinical endpoints such hepatic decompensations, transplant free survival, and all-cause mortality, although these results are not necessarily needed prior to drug approval given the long length of follow up potentially required
Statistical modeling was used to analyze the association between GLP-1 exposure and breast cancer incidence
P., & Ren, Z
3 Given it is still in the early days regarding the success and second-order effects of these drugs, its difficult to determine if the impact on various areas of the stock market is short-lived
